Medical Developments International (ASX:MVP) — Material Events
ASX:MVP · 4 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Medical Developments International Posts 9% Revenue Growth and 566% Profit Surge on Penthrox ExpansionMedium
Medical Developments International reports 9% revenue growth and 566% profit increase for FY26, driven by Pain Management segment
20 Aug 2026
·Preliminary Final Report and Annual Financial Report
·Unexpected
·85
Medical Developments International Boosts Penthrox Sales and Advances Paediatric ApprovalMedium
Medical Developments International posts Q1 revenue growth and strong cash flow; advances Penthrox paediatric approvals
10 Oct 2025
·Quarterly Activity Report and Appendix 4C
·80
MVP Boosts Penthrox Sales Amid EBIT Challenges in FY26 H1Medium
MVP H1 FY26 revenue up 8%, Penthrox volume growth strong; EBIT loss narrows excluding FX impact
19 Feb 2026
·Half Year Results
·75
No articles in this tier for the last 12 months.
Market Mentions
2
- appeared in market wrap coverage
These are market wrap articles where Medical Developments International (ASX:MVP) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026
22 Aug 2026
Healthcare Wrap - Week 8 (16 Feb -> 20 Feb) 2026
21 Feb 2026